Psoriasis is a chronic, inflammatory multisystem disease that affects up to 3.2% of the US population. This guideline addresses important clinical questions that arise in psoriasis management and care, providing recommendations based on the available evidence. The treatment of psoriasis with biologic agents will be reviewed, emphasizing treatment recommendations and the role of the dermatologist in monitoring and educating patients regarding benefits as well as associated risks
The overall aim of the guideline is to provide up‐to‐date, evidence‐based recommendations on the use...
Psoriasis is one of the most common chronic inflammatory skin disorders worldwide with a significant...
Alefacept, efalizumab, etanercept, and infliximab are currently approved for the treatment of adults...
Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US populati...
Psoriasis is a chronic, inflammatory, multisystem disease which affects up to 3.2% of the U.S popula...
Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approxima...
Psoriasis is a chronic inflammatory skin disease that affects over 100 million people worldwide.1 It...
The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic...
The aim of this guideline is to provide an update on evidence-based recommendations for treatment of...
The aim of this guideline is to provide an update on evidence-based recommendations for treatment of...
The advent of biologic agents within the past two decades has dramatically improved the treatment of...
AbstractPsoriasis is a chronic, noncontiguous, inflammatory, multisystem disease with predominantly ...
Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children,...
Objective. To develop an evidence- based guideline for the pharmacologic and nonpharmacologic treatm...
Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that ...
The overall aim of the guideline is to provide up‐to‐date, evidence‐based recommendations on the use...
Psoriasis is one of the most common chronic inflammatory skin disorders worldwide with a significant...
Alefacept, efalizumab, etanercept, and infliximab are currently approved for the treatment of adults...
Psoriasis is a chronic, inflammatory, multisystem disease that affects up to 3.2% of the US populati...
Psoriasis is a chronic, inflammatory, multisystem disease which affects up to 3.2% of the U.S popula...
Psoriasis is a chronic inflammatory disease involving multiple organ systems and affecting approxima...
Psoriasis is a chronic inflammatory skin disease that affects over 100 million people worldwide.1 It...
The overall aim of the guideline is to provide evidence-based recommendations on the use of biologic...
The aim of this guideline is to provide an update on evidence-based recommendations for treatment of...
The aim of this guideline is to provide an update on evidence-based recommendations for treatment of...
The advent of biologic agents within the past two decades has dramatically improved the treatment of...
AbstractPsoriasis is a chronic, noncontiguous, inflammatory, multisystem disease with predominantly ...
Psoriasis is a chronic, multisystem, inflammatory disease that affects approximately 1% of children,...
Objective. To develop an evidence- based guideline for the pharmacologic and nonpharmacologic treatm...
Psoriasis is a genetically determined, systemic immune-mediated chronic inflammatory disease that ...
The overall aim of the guideline is to provide up‐to‐date, evidence‐based recommendations on the use...
Psoriasis is one of the most common chronic inflammatory skin disorders worldwide with a significant...
Alefacept, efalizumab, etanercept, and infliximab are currently approved for the treatment of adults...